Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
NAS:ECYT's Cash-to-Debt is ranked higher than
68% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: 49.39 vs. NAS:ECYT: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:ECYT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.69  Med: 9999.5 Max: No Debt
Current: No Debt
Equity-to-Asset 0.97
NAS:ECYT's Equity-to-Asset is ranked higher than
96% of the 483 Companies
in the Global Biotechnology industry.

( Industry Median: 0.63 vs. NAS:ECYT: 0.97 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:ECYT' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.45  Med: 0.93 Max: 0.97
Current: 0.97
0.45
0.97
Interest Coverage No Debt
NAS:ECYT's Interest Coverage is ranked higher than
75% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:ECYT: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:ECYT' s Interest Coverage Range Over the Past 10 Years
Min: 5027  Med: 7513.5 Max: No Debt
Current: No Debt
Piotroski F-Score: 4
Altman Z-Score: 7.64
Beneish M-Score: -3.93
WACC vs ROIC
13.63%
-4940.62%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -60206.94
NAS:ECYT's Operating Margin % is ranked lower than
98% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -50.65 vs. NAS:ECYT: -60206.94 )
Ranked among companies with meaningful Operating Margin % only.
NAS:ECYT' s Operating Margin % Range Over the Past 10 Years
Min: -60206.94  Med: -524.6 Max: 7.15
Current: -60206.94
-60206.94
7.15
Net Margin % -59190.28
NAS:ECYT's Net Margin % is ranked lower than
98% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -43.94 vs. NAS:ECYT: -59190.28 )
Ranked among companies with meaningful Net Margin % only.
NAS:ECYT' s Net Margin % Range Over the Past 10 Years
Min: -59190.28  Med: -566.87 Max: 7.76
Current: -59190.28
-59190.28
7.76
ROE % -26.15
NAS:ECYT's ROE % is ranked lower than
52% of the 544 Companies
in the Global Biotechnology industry.

( Industry Median: -24.74 vs. NAS:ECYT: -26.15 )
Ranked among companies with meaningful ROE % only.
NAS:ECYT' s ROE % Range Over the Past 10 Years
Min: -492.46  Med: -19.2 Max: 3.72
Current: -26.15
-492.46
3.72
ROA % -25.25
NAS:ECYT's ROA % is ranked lower than
52% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: -21.99 vs. NAS:ECYT: -25.25 )
Ranked among companies with meaningful ROA % only.
NAS:ECYT' s ROA % Range Over the Past 10 Years
Min: -91.6  Med: -37.06 Max: 2.91
Current: -25.25
-91.6
2.91
ROC (Joel Greenblatt) % -1242.02
NAS:ECYT's ROC (Joel Greenblatt) % is ranked lower than
70% of the 585 Companies
in the Global Biotechnology industry.

( Industry Median: -218.94 vs. NAS:ECYT: -1242.02 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:ECYT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3911.11  Med: -1386.73 Max: 128.73
Current: -1242.02
-3911.11
128.73
3-Year Revenue Growth Rate -87.30
NAS:ECYT's 3-Year Revenue Growth Rate is ranked lower than
91% of the 435 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. NAS:ECYT: -87.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:ECYT' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -87.3 Max: 522.1
Current: -87.3
0
522.1
3-Year EBITDA Growth Rate 29.10
NAS:ECYT's 3-Year EBITDA Growth Rate is ranked higher than
80% of the 469 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. NAS:ECYT: 29.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:ECYT' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -70.6 Max: 29.1
Current: 29.1
0
29.1
3-Year EPS without NRI Growth Rate 26.90
NAS:ECYT's 3-Year EPS without NRI Growth Rate is ranked higher than
80% of the 459 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. NAS:ECYT: 26.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:ECYT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -71.05 Max: 26.9
Current: 26.9
0
26.9
GuruFocus has detected 1 Warning Sign with Endocyte Inc $NAS:ECYT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:ECYT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ECYT Guru Trades in Q1 2016

Jim Simons 63,400 sh (+23.92%)
» More
Q2 2016

ECYT Guru Trades in Q2 2016

Jim Simons Sold Out
» More
Q3 2016

ECYT Guru Trades in Q3 2016

Jim Simons 189,000 sh (New)
» More
Q4 2016

ECYT Guru Trades in Q4 2016

Jim Simons 50,100 sh (-73.49%)
» More
» Details

Insider Trades

Latest Guru Trades with ECYT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:CASI, AMEX:SYN, NAS:NEPT, AMEX:XXII, AMEX:CRMD, NAS:SNSS, NAS:ARQL, OTCPK:HBPCF, NAS:ORMP, OTCPK:ORGS, NAS:CASC, AMEX:ATNM, NAS:TTNP, OTCPK:PMCB, NAS:GTXI, NAS:BCLI, NAS:VCEL, NAS:CRME, NAS:IPCI, AMEX:NAVB » details
Traded in other countries:9EY.Germany,
Endocyte Inc is a biopharmaceutical company. The Company is engaged in developing targeted therapies for the treatment of cancer and inflammatory diseases.

Endocyte Inc was incorporated in the State of Indiana in 1995 and was reincorporated in the State of Delaware in 2001. The Company completed its initial public offering on April 2, 2014. The Company is a biopharmaceutical company. The Company is engaged in developing targeted therapies for the treatment of cancer and inflammatory diseases. It uses its proprietary technology to create novel small molecule drug conjugates, or SMDCs, and companion imaging agents. The Company is also developing companion imaging agents for each of its SMDCs that are designed to identify the patients whose disease over-expresses the target of the therapy and who are therefore likely to benefit from treatment. Its SMDC candidate, vintafolide, targets the folate receptor, which is frequently over-expressed on cancer cells. The Company's SMDC Pipeline products include Vintafolide designed to deliver a cytotoxic drug payload directly to folate receptors that are over-expressed on cancer cells, with low toxicity to healthy cells; EC1456 is a second generation folate receptor-targeted SMDC. It is a conjugate of folate and an anti-cancer drug payload of tubulysin, a microtubule destabilizer; EC1169 is non-folate targeted SMDC and is designed to specifically target PSMA; EC1788 is a folate receptor-targeted SMDC in preclinical development with a very potent DNA alkylator drug; EC1669 is a folate receptor-targeted SMDC in preclinical development for treatment in inflammatory diseases; and EC0371 is a folate receptor-targeted SMDC in preclinical development for treatment of polycystic kidney disease. The Company faces competition from other pharmaceutical companies, biotechnology companies, public and private universities and research organizations. Government authorities in the United States (including federal, state and local authorities) and in other countries regulate, among other things, the manufacturing, research and clinical development, marketing, labeling and packaging, distribution, post-approval monitoring and reporting, advertising and promotion, and export and import of pharmaceutical products.

Ratios

vs
industry
vs
history
PB Ratio 0.65
ECYT's PB Ratio is ranked higher than
96% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. ECYT: 0.65 )
Ranked among companies with meaningful PB Ratio only.
ECYT' s PB Ratio Range Over the Past 10 Years
Min: 0.58  Med: 1.3 Max: 11.65
Current: 0.65
0.58
11.65
EV-to-EBIT 1.23
ECYT's EV-to-EBIT is ranked higher than
87% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 18.89 vs. ECYT: 1.23 )
Ranked among companies with meaningful EV-to-EBIT only.
ECYT' s EV-to-EBIT Range Over the Past 10 Years
Min: -50.6  Med: -1.35 Max: 29.5
Current: 1.23
-50.6
29.5
EV-to-EBITDA 1.26
ECYT's EV-to-EBITDA is ranked higher than
88% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 16.23 vs. ECYT: 1.26 )
Ranked among companies with meaningful EV-to-EBITDA only.
ECYT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -57.6  Med: -1.4 Max: 25.2
Current: 1.26
-57.6
25.2
Current Ratio 32.64
ECYT's Current Ratio is ranked higher than
97% of the 585 Companies
in the Global Biotechnology industry.

( Industry Median: 3.45 vs. ECYT: 32.64 )
Ranked among companies with meaningful Current Ratio only.
ECYT' s Current Ratio Range Over the Past 10 Years
Min: 1.26  Med: 8.42 Max: 38
Current: 32.64
1.26
38
Quick Ratio 32.64
ECYT's Quick Ratio is ranked higher than
97% of the 583 Companies
in the Global Biotechnology industry.

( Industry Median: 3.24 vs. ECYT: 32.64 )
Ranked among companies with meaningful Quick Ratio only.
ECYT' s Quick Ratio Range Over the Past 10 Years
Min: 1.26  Med: 8.42 Max: 38
Current: 32.64
1.26
38
Days Sales Outstanding 101.39
ECYT's Days Sales Outstanding is ranked lower than
73% of the 405 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. ECYT: 101.39 )
Ranked among companies with meaningful Days Sales Outstanding only.
ECYT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 3.66  Med: 41.34 Max: 101.39
Current: 101.39
3.66
101.39

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -5.20
ECYT's 3-Year Average Share Buyback Ratio is ranked higher than
69% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -10.60 vs. ECYT: -5.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ECYT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -240.4  Med: -5.3 Max: 0
Current: -5.2
-240.4
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 0.66
ECYT's Price-to-Net-Cash is ranked higher than
99% of the 295 Companies
in the Global Biotechnology industry.

( Industry Median: 7.38 vs. ECYT: 0.66 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ECYT' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.61  Med: 2.62 Max: 32.02
Current: 0.66
0.61
32.02
Price-to-Net-Current-Asset-Value 0.65
ECYT's Price-to-Net-Current-Asset-Value is ranked higher than
99% of the 387 Companies
in the Global Biotechnology industry.

( Industry Median: 6.60 vs. ECYT: 0.65 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ECYT' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.6  Med: 2.43 Max: 17.28
Current: 0.65
0.6
17.28
Price-to-Tangible-Book 0.63
ECYT's Price-to-Tangible-Book is ranked higher than
97% of the 494 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. ECYT: 0.63 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ECYT' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.58  Med: 1.71 Max: 9.84
Current: 0.63
0.58
9.84
Price-to-Median-PS-Value 110.50
ECYT's Price-to-Median-PS-Value is ranked lower than
99% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 0.99 vs. ECYT: 110.50 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ECYT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.15  Med: 0.9 Max: 229
Current: 110.5
0.15
229
Earnings Yield (Greenblatt) % 81.05
ECYT's Earnings Yield (Greenblatt) % is ranked higher than
96% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: -6.50 vs. ECYT: 81.05 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ECYT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.4  Med: 126.8 Max: 2545.1
Current: 81.05
3.4
2545.1

More Statistics

Revenue (TTM) (Mil) $0.07
EPS (TTM) $ -1.01
Beta1.50
Short Percentage of Float3.88%
52-Week Range $1.98 - 4.33
Shares Outstanding (Mil)42.27

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $)
EPS ($) -1.05 -1.29 -1.10 -1.12
EPS without NRI ($) -1.05 -1.29 -1.10 -1.12
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ECYT

Headlines

Articles On GuruFocus.com
Merck: Ready to Rise on New Drugs Apr 18 2012 

More From Other Websites
Endocyte (ECYT) to Post Q4 Earnings: What's in the Cards? Feb 23 2017
ENDOCYTE INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and... Feb 21 2017
Endocyte Appoints Michael T. Andriole as Chief Financial Officer Feb 21 2017
Valeant Streamlines Portfolio with Skincare Brands Sale Jan 11 2017
Valeant to Sell Dendreon Unit to Sanpower for $820 Million Jan 10 2017
Is Valeant (VRX) Fated for Terrible 2017 As Well? Jan 03 2017
How Endocyte, Inc. (ECYT) Stacks Up Against Its Peers Dec 15 2016
ETFs with exposure to Endocyte, Inc. : December 14, 2016 Dec 14 2016
Mission Therapeutics Appoints Colin Goddard as Chairman Dec 05 2016
Endocyte to Present at the IASLC 17th World Conference on Lung Cancer Dec 01 2016
ETFs with exposure to Endocyte, Inc. : November 29, 2016 Nov 29 2016
Endocyte, Inc. :ECYT-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016 Nov 28 2016
ENDOCYTE INC Financials Nov 17 2016
Endocyte (ECYT) Stock Up on Lower-than-Expected Q3 Loss Nov 11 2016
Endocyte Reports Third Quarter 2016 Financial Results Nov 09 2016
ENDOCYTE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Nov 09 2016
Endocyte Announces Third Quarter 2016 Earnings Conference Call Nov 02 2016
Endocyte (ECYT): Can the Stock Surprise in Q3 Earnings? Oct 28 2016
ENDOCYTE INC Files SEC form 8-K, Change in Directors or Principal Officers Oct 20 2016
ENDOCYTE INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Oct 11 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)